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RESEARCH ARTICLE
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Abstract
Respiratory syncytial virus (RSV) is the most common cause of infant hospitalizations and
severe RSV infections are a significant risk factor for childhood asthma. The pathogenic
mechanisms responsible for RSV induced immunopathophysiology remain elusive. Using
an age-appropriate mouse model of RSV, we show that IL-33 plays a critical role in the
immunopathogenesis of severe RSV, which is associated with higher group 2 innate lym-
phoid cells (ILC2s) specifically in neonates. Infection with RSV induced rapid IL-33 expres-
sion and an increase in ILC2 numbers in the lungs of neonatal mice; this was not observed
in adult mice. Blocking IL-33 with antibodies or using an IL-33 receptor knockout mouse dur-
ing infection was sufficient to inhibit RSV immunopathogenesis (i.e., airway hyperrespon-
siveness, Th2 inflammation, eosinophilia, and mucus hyperproduction); whereas
administration of IL-33 to adult mice during RSV infection was sufficient to induce RSV dis-
ease. Additionally, elevated IL-33 and IL-13 were observed in nasal aspirates from infants
hospitalized with RSV; these cytokines declined during convalescence. In summary, IL-33
is necessary, either directly or indirectly, to induce ILC2s and the Th2 biased immunopatho-
physiology observed following neonatal RSV infection. This study provides a mechanism
involving IL-33 and ILC2s in RSV mediated human asthma.
Author Summary
IL-33 is responsible for the immunopathophysiological response observed following neo-
natal RSV infection in mice. Its presence in nasal aspirates of human infants with severe
RSV and suggests its role in disease severity and asthma.
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Introduction
Respiratory syncytial virus (RSV) is the most common cause of lower respiratory tract infec-
tions in infants [1, 2], and is globally responsible for an estimated 64 million cases and 160,000
deaths each year [2]. In infants, severe RSV infection is characterized by bronchiolitis, intersti-
tial pneumonitis, alveolitis [3], and a T helper 2 (Th2)-biased immune response in the lungs
(i.e., Th2 cells, eosinophilia, mucus). One important correlate of severe RSV infection is age;
most severe disease occurs in children<1 yr of age [4], with highest hospitalization rates
occurring in those<6 months of age [5]. More recently, our understanding of RSV has been
aided by the use of an age-appropriate mouse model in which neonatal mice infected with RSV
exhibit an immunological (Th2 biased) and pathophysiological (pulmonary inflammation,
eosinophilia, mucus hyperproduction, and long-term airways dysfunction) phenotype typically
seen in human infants with severe RSV [6, 7].
We previously observed an early increase in IL-13 in the lungs of neonatal, but not adult
mice, infected with RSV, which could not be explained by Th2 cells. Group 2 innate lymphoid
cells (ILC2s) are a recently identified cell population naturally resident to the lungs that rapidly
respond to IL-33 via its receptor ST2 to produce high levels of IL-13 [8]. It has been demon-
strated that ILC2s play a critical role in the induction of Th2 immune responses [8–10].
Though ILC2s and IL-33 have both been closely associated with Th2 immunity, there are no
data discerning either’s roles in the initiation and/or perpetuation of Th2 responses observed
in infant RSV infection. This comes despite the fact that numerous studies show high correla-
tion between genetic variation in the IL33 or ST2 genes and risk for asthma or severe RSV dis-
ease [11–13]–including a recent meta-analysis of GWAS studies which identifies ST2 as one of
the top ten loci that influence allergic sensitization [14]. This information, combined with the
fact that ILC2s appear to be essential for early production of IL-13 during viral infections [15],
makes ILC2s and IL-33 prime targets for the study of Th2-biased infant RSV disease.
In the present study, we show that IL-33 is rapidly secreted in the lungs of neonatal mice
infected with RSV, which is accompanied by an increase in lung ILC2s. This response is age-
specific, as RSV infection in adult mice does not induce increases in IL-33 or ILC2s. We further
demonstrate that Th2-biased immunopathophysiology that occurs upon reinfection with RSV
is IL-33-dependent.
Results
RSV induces robust, rapid IL-33 and IL-13 production in the lungs of
neonates
We previously observed an increase in pulmonary IL-13 immediately following RSV infection
of neonatal, but not, adult mice. Since this increase was prior to the induction of Th2 cells and
responses, it suggested a role for ILC2s. To determine if there are age-dependent differences in
the induction of ILC2s in response to RSV, we infected neonatal mice (5 d of age; NR) and
adult mice (6–8 weeks of age; AR) then kinetically measured IL-33 and IL-13 cytokine levels in
whole lung homogenates (Fig 1a). Highly elevated IL-33 levels were detected in neonates as
early as 0.25 days post-infection (dpi) and peaking at 0.5 dpi. Although IL-33 could be detected
in the lungs of adult mice, there was no significant change in expression following RSV infec-
tion. A similar trend was observed with IL-13 levels—increased expression in the lungs of mice
infected as neonates, which peaked at 1 dpi, and no significant change in the lungs of mice
infected as adults. An additional significant increase in IL-13 was observed at 6 dpi in mice
infected as neonates. Significantly elevated levels of IL-33 were also observed in bronchoalveo-
lar lavage (BAL) from infected neonates but not adults (Fig 1b). Investigation into the cellular
IL-33 and ILC2s in Infant RSV Infection
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sources of IL-33 at 1 dpi revealed significant expression in airway epithelial cells (CD45-
EpCam+) of infected neonates (Fig 1c). A similar trend was observed with detection of IL-33
mRNA by in situ hybridization (Fig 1d). To determine if this rapid IL-33 increase in neonates
requires live replicating virus, we “infected” neonates with UV-inactivated RSV (UV-RSV) and
measured IL-33 in lung homogenates at 1 dpi (Fig 1e). IL-33 levels in the lungs following
administration of UV-RSV was statistically no different than sham infected neonatal control
mice and significantly lower than RSV infected neonatal mice.
Fig 1. RSV induces robust, rapid IL-33 and IL-13 production in the lungs of neonates. (a) Cytokine protein levels of IL-33 and IL-13 in whole lung
homogenates of RSV-infected neonate (5-day-old; NR) and adult (6-8-week-old; AR) mice (n = 4–10 per group) at different days (0–10) post-infection (dpi).
(b) Cytokine protein levels of IL-33 detected in BAL at 1 dpi from NR and ARmice (n = 8–10 per group) compared to controls. (c) Gating strategy for
determination of IL-33 expression by median fluorescence intensity (MFI) in epithelial cells (CD45- EpCam+) with representative IL-33 MFI histogram
(quantified in inset vs. fluorescence-minus-one (FMO) control (dotted line)). (d) Representative micrographs of in situ hybridization for IL-33 mRNAwith red
arrows to indicate positive staining cells (top), magnified inset (bottom), and quantification of IL-33 mRNA positive cells per unit area of lung. Scale
bar = 100 μm. (e) Cytokine protein levels of IL-33 in whole lung homogenates of neonates infected with RSV or UV-RSV compared to control at 1 dpi.
*P < 0.05 (Student’s t-test; a, c, d) (Two-way ANOVA; b) (One-way ANOVA; e). Data are representative of two (a, c) or 2 pooled (b, d, e) independent
experiments (means ± s.e.m).
doi:10.1371/journal.ppat.1005217.g001
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The percentage of ILC2s in the lungs of neonatal mice are further
increased after RSV infection
Of note, neonatal mice displayed 3–4 fold more lung ILC2s (lineage- CD45+ ICOS+ ST2+; gat-
ing strategy in S1 Fig; raw numbers in S3 Fig) at baseline (i.e. prior to infection) compared to
adults (Fig 2a–2c). After infection, lung ILC2 percentages at 1 dpi were significantly higher in
RSV-infected neonates compared to adults. Furthermore, neonatal ILC2s expressed more ST2
(Fig 2d). There was no change in the frequency of ILC2s at baseline or at 1dpi (Fig 2c) or in
ST2 levels on those ILC2s at baseline or at 1dpi (Fig 2d) in adults.
Modulation of IL-33 levels during primary RSV infection alters ILC2
numbers and IL-13 production at 1 dpi
Because our data showed increased IL-33 in the lungs of RSV-infected neonates, but not adults,
we pretreated neonates with anti-IL-33 antibody (α-IL-33+NR) and pretreated adults with
recombinant IL-33 (rIL-33+AR) prior to RSV infection (see methods). When IL-33 was neu-
tralized during primary RSV infection in neonates, the number of ILC2s and ST2 expression
by those ILC2s was decreased compared to controls, while the opposite effect was seen in adults
given rIL-33 (Fig 3a). Additionally, lung levels of IL-13 were statistically decreased/increased
depending upon IL-33 neutralization/augmentation, respectively (Fig 3b). To determine if IL-
33 modulation had an impact on overall viral load, we compared the amount of infectious
virus in the lungs of treated and control mice at the peak of infection (i.e. 4 dpi) (Fig 3c). Inter-
estingly, IL-33 neutralization had no effect on RSV burden in neonates, but we observed a sig-
nificant decrease in viral load in adult mice pre-treated with rIL-33.
IL-33 levels during primary RSV infection determine disease severity
after reinfection
In infants, severe RSV often causes bronchiolitis, recruitment of inflammatory cells (i.e., Th2
cells, eosinophils) to the lungs, and increased airway mucus, resulting in significant airway
obstruction and airway hyperresponsiveness (AHR). A similar disease phenotype is readily
observed (following reinfection) in mice initially infected with RSV as neonates, but not adults.
To phenotypically recapitulate severe RSV infection seen clinically in human infants, mice
from the same treatment groups as in Fig 3 were reinfected with RSV at 4 weeks post-primary
infection (established neonatal mouse RSV infection + reinfection protocol [6, 7, 16]) and
immune responses determined at 6 dpi (Fig 4). Neutralizing IL-33 during primary infection in
neonates resulted in significant reductions in Th2 and multifunctional Th (mTh; IFNγ+, IL-4+)
cells upon reinfection (α-IL-33+NRR) (Fig 4a). Conversely, administration of rIL-33 to adult
mice during primary infection resulted in significant increases in Th2 and mTh cells upon rein-
fection (rIL-33+ARR), which were similar to levels induced in NRR mice.
Similar trends were observed in other markers of disease severity; when IL-33 was neutral-
ized during primary RSV infection in neonates, development of AHR was abolished (Fig 4b).
Interestingly, IL-33 administration to adult mice during primary infection resulted in exacer-
bated AHR, significantly above that of the NRR group. In the absence of RSV infection, neither
IL-33 neutralization in neonates nor rIL-33 administration in adults resulted in AHR (S2 Fig).
Cellularity in BAL from these same treatment groups displayed decreases in total cells, lympho-
cytes, and eosinophils in α-IL-33+NRR mice, and an increase in eosinophils in rIL-33+ARR
mice (Fig 4c).
Lung sections were stained with periodic acid-Schiff (PAS) to visualize mucus-producing
cells in the airways. Airway mucus production was significantly decreased in α-IL-33+NRR
IL-33 and ILC2s in Infant RSV Infection
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mice compared to controls, while mucus was significantly increased in rIL-33+ARR mice com-
pared to controls (Fig 5a and 5b).
IL-33 signaling is required for neonatal RSV immunopathophysiology
To further demonstrate the role of IL-33 in promoting enhanced RSV disease in infected neo-
nates, ST2 (IL-33 receptor, Il1rl1-/-)-deficient neonatal mice were infected with RSV as in Figs
4, 5 and 6. Compared to similarly-infected wild type mice (WT NRR), Il1rl1-/- NRR mice failed
to develop significant Th2 or mTh adaptive responses (Fig 6a), did not exhibit AHR (Fig 6b),
and had decreased total cells, lymphocytes, and eosinophils in BAL (Fig 6c).
Fig 2. The percentage of ILC2s in the lungs of neonatal mice are further increased after RSV infection. (a) Gating strategy and (b) ILC2 marker
expression on ILC2s at baseline and 1 dpi. (c) ILC2s as percent of total lung cells, and (d) MFI of ST2 expression of/on ILC2s at baseline and 1 dpi. ILC2s
defined as lineage- CD45+ ICOS+ ST2+ with gating based on FMO controls. *P < 0.05 (Two-way ANOVA). Data are representative of four independent
experiments (means ± s.e.m).
doi:10.1371/journal.ppat.1005217.g002
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IL-33 and IL-13 concentrations are elevated in nasal aspirates from
infants hospitalized with RSV infection
Nasal aspirates were obtained from RSV-infected human infants (n = 81) on their initial day of
clinical presentation (d1) at Le Bonheur Children’s Hospital. A follow-up nasal aspirate sample
was obtained from some patients (n = 19) four weeks later (d28). Cytokine concentrations
were analyzed in cell and mucus-free supernatants (Fig 7). In the paired samples, IL-33 and IL-
13 levels were significantly elevated in d1 aspirates compared to d28 (Fig 7a). For all d1 sam-
ples, IL-33 levels significantly correlated with IL-13 (Fig 7b).
Discussion
Infant susceptibility to severe RSV infection remains a significant global health burden for
which no protective vaccine or adequate therapeutic is yet available. In recent years, it has
become increasingly clear that age-dependent inherent differences in immunity play a vital
role in both the magnitude [17, 18] and type [7] of responses to RSV. Interestingly, while
infants are capable of mounting robust type-1 responses to other respiratory viruses such as
influenza [19], they uniquely favor type-2 responses and the development of Th2 adaptive
immunity (i.e. elevated IL-13 compared to IFN-γ) to RSV. Age at initial infection is critical in
determining initial and subsequent immune responses to RSV [20] and in predicting subse-
quent wheeze/asthma [6, 7, 21, 22]. The role of age in dictating the response to RSV remains
incompletely understood with respect to mechanism.
Fig 3. Modulation of IL-33 levels during primary RSV infection alters ILC2 numbers and IL-13
production at 1 dpi. (a) Number of ILC2s (lineage- CD45+ ICOS+ ST2+) expressed as percentage of total
lung cells and MFI of surface ST2 on ILC2s at 1 dpi in neonatal mice pretreated with IL-33 neutralizing
antibody (α-IL-33 + NR) or control IgG antibody (Isotype + NR) and adult mice pretreated with recombinant IL-
33 (rIL-33 + AR) or vehicle control (Control + AR). (n = 5–7 per group). (b) IL-13 protein levels in whole lung
homogenates. (c) Pulmonary viral loads measured at 4 dpi (peak) using the TCID50 method. *P < 0.05 vs.
indicated group, (Student’s t-test). Data are representative of two independent experiments (means ± s.e.m).
doi:10.1371/journal.ppat.1005217.g003
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In the present study, we observed higher levels of lung ILC2s in neonates and an age depen-
dent induction of ILC2s following RSV infection (i.e. ILC2s were only induced if the initial
infection with RSV occurred in neonates). Our data resembles the seminal data demonstrating
a role for ILC2s in the induction of AHR following influenza infection [15] with the exception
that adult mice were infected with influenza and no data were presented on the Th subtypes
following that infection or a subsequent infection. However, our data with RSV are in-line with
recent data demonstrating an age dependent ILC2 response to rhinovirus in mice (i.e. increases
in ILC2s in neonates but a minimal effect in adults) [23]. A potential difference between our
results and those with neonatal rhinovirus is the cytokine responsible for driving ILC2
Fig 4. IL-33 levels during primary RSV infection determine disease severity after reinfection. (a) Number of Th1 (CD3+CD4+IFNγ+), Th2 (CD3+CD4+IL-
4+), and multifunctional Th (CD3+CD4+IFNγ+IL-4+; mTh) cells in the lungs of mice at 6 dpi following reinfection with RSV (methods) (n = 5–6 per group); prior
to initial RSV infection, neonatal mice were pretreated with IL-33 neutralizing antibody (α-IL-33 + NRR) or control IgG antibody (Isotype + NRR) and adult
mice pretreated with recombinant IL-33 (rIL-33 + ARR) or vehicle control (Control + ARR). (b) Change in airway resistance in response to increasing doses of
inhaled methacholine after treatment as in a (n = 6–8 per group). (c) Total cells (Total), monocytes/macrophages (Mo/MΦ), lymphocytes (Lymph), neutrophils
(Neutro), and eosinophils (Eos) in BAL fluid after treatment as in a (n = 3–6 per group). *P < 0.05 vs. indicated group (one-way ANOVA with Bonferroni post-
hoc tests; a, c) (two-way ANOVA with Bonferroni post-hoc tests; b). Data are representative of at least two independent experiments (means ± s.e.m).
doi:10.1371/journal.ppat.1005217.g004
IL-33 and ILC2s in Infant RSV Infection
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induction; with rhinovirus, ILC2s were IL-25 dependent whereas ILC2 induction with RSV
appears to be IL-33 dependent and not IL-25 dependent. This is intriguing, although the mech-
anism at this time is unclear, since both RSV and rhinovirus cause severe infection and type-2
inflammation during infancy, and it is those with severe infection that are at greatest risk for
Fig 5. IL-33 levels during primary RSV infection determine disease severity after reinfection. (a) Lung sections obtained frommice treated as in Fig 4,
stained with periodic acid-Schiff (PAS) to observe mucus (bright purple; indicated by black arrowheads). Upper images taken at 100X with inset (black box)
magnified underneath to 400X. (b) Quantification of airway mucus in mice treated as in a (methods). *P < 0.05 vs. indicated group (one-way ANOVA with
Bonferroni post-hoc tests). Data are representative of two independent experiments (means ± s.e.m).
doi:10.1371/journal.ppat.1005217.g005
Fig 6. IL-33 signaling is required for neonatal RSV immunopathophysiology. (a) Number of Th1, Th2,
and multifunctional mTh cells in the lungs of wild-type (WT) or ST2-deficient (Il1rl1-/-) mice at 6 dpi following
reinfection with RSV (methods) (n = 5–6 per group). (b) Change in airway resistance in response to
increasing doses of inhaled methacholine after treatment as in a (n = 6 per group), compared to naïve control
mice of similar size and age. (c) Total cells (Total), monocytes/macrophages (Mo/MΦ), lymphocytes
(Lymph), neutrophils (Neutro), and eosinophils (Eos) in BAL fluid after treatment as in a (n = 5–8 per group).
*P < 0.05 (Student’s t-test (a, c) or two-way ANOVA with Bonferroni post-hoc tests (b)). Data are
representative of two independent experiments (means ± s.e.m).
doi:10.1371/journal.ppat.1005217.g006
IL-33 and ILC2s in Infant RSV Infection
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long term airways disease [21]. Combined, the data from these studies expand the mechanistic
knowledge of age-dependent type-2 immunity “bias” observed clinically in infants.
Severe RSV infection during infancy is heavily associated with the development of wheeze
and/or allergic asthma during childhood and early adult life [21, 22, 24–26], and various
genetic studies in humans have identified both IL-33 and ST2 as being key regulators in the
development of asthma [11–14]. Our results demonstrate, for the first time, the vital age-
dependent role of IL-33 in RSV-mediated Th2 immunopathophysiology. Levels of IL-33 dur-
ing infection was influenced by age at the time of initial infection; and this, in turn, correlated
with an increase in the numbers of lung ILC2s coinciding with enhanced IL-13 expression and
increased lung dysfunction (i.e. AHR) and pathology. In this study, IL-33 neutralization during
initial RSV infection in the neonate was sufficient to completely abolish the severe RSV pheno-
type (i.e., Th2 inflammation, AHR, eosinophilia, airway mucus), while administration of rIL-
33 during initial infection in adult mice was sufficient to induce the severe RSV phenotype.
Notably, these IL-33 effects during neonatal RSV infection appeared to be through changes in
innate (i.e. ILC2) and adaptive (i.e. Th2) immunity and not via changes in viral load. The
effects of rIL-33 during adult RSV also appeared to be mediated through innate and adaptive
immunity; however, the counterintuitive decrease in viral load in rIL-33 treated mice suggests
that its influence is more complex.
The strong Th2-promoting ability of IL-33-activated ILC2s has been largely demonstrated
in animal models of Th2 disease such as asthma [10, 27] and helminth infection [8, 28]. It has
been shown that ILC2s influence adaptive T cell responses both directly through MHCII-medi-
ated crosstalk [29] and indirectly through Th2 cytokine production. Despite the severe immu-
nopathophysiology we observed in rIL-33 treated adult mice infected with RSV, these mice
displayed a significant yet relatively moderate increase in ILC2s during infection. Given the dis-
parity in ILC2s between rIL-33 treated adult mice and neonatal mice, yet similar severity of
RSV disease, it is probable that lung dendritic cells (DCs) are playing a large role in this model.
In addition to activating ILC2s, IL-33 activates lung DCs via OX40L upregulation [30] to pro-
mote Th2 differentiation of naïve lymphocytes [31] and exacerbates eosinophilia [32]. Further-
more, blocking OX40L abrogates severe RSV in neonatal mice [33]. DCs are also important for
anti-RSV responses, namely production of type-I interferons (i.e., IFNα, IFNβ), which are also
impaired in RSV-infected infants [18, 34]. We have observed IL-13-mediated Th2 promotion
Fig 7. IL-33 and IL-13 concentrations are elevated in nasal aspirates from infants hospitalized with RSV infection. (a) Concentrations of IL-33 and IL-
13 in nasal aspirates taken from RSV-infected infants (n = 19) on the first day (d1) of clinical presentation to Le Bonheur Children’s Hospital and again four
weeks later (d28). (b) Correlation of IL-33 and IL-13 concentrations for all patients with d1 samples (n = 81). Samples with cytokine concentrations below the
LOD of the assay are replaced by a value equal to the LOD divided by the square root of 2, and denoted with a filled circle. *P < 0.05 (Sign test (a) or
Kendall’s tau correlation (b)).
doi:10.1371/journal.ppat.1005217.g007
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by DCs in RSV (manuscript in preparation), and the rapidity of IL-13 expression following
RSV infection suggests ILC2s as the source. We are currently investigating the ability of ILC2s,
IL-33, and IL-13 to negatively influence type-I interferon production by pDCs. A role for DCs
is currently being explored.
Though not as robust as earlier timepoints, a second, additional increase in IL-13 was
observed at 6 dpi of initial infection. The significant increase in Th2 cells that has also been
observed at 6 dpi suggests that they are at least partly responsible for elevated IL-13 levels at
this time point.
The receptor for IL-33, ST2, also exists in a soluble secreted form (sST2), which scavenges
“free” IL-33 [35]. One would expect that increased IL-33 scavenging ability would correlate
with decreased disease severity, as mice that overexpress sST2 display resistance to IL-
33-induced inflammation [36]. However, IL-33 has been shown to upregulate sST2 levels,
which subsequently reduces IL-33 levels [37]. Interestingly, sST2 has been detected in higher
concentrations in nasal aspirates of severely RSV-infected infants requiring mechanical ventila-
tion compared to mild/moderately-infected, non-ventilated infants [13]. This same study also
identified SNPs in the sST2-encoding gene in these individuals; one of which correlated with
disease severity. While it is unclear if this SNP is responsible for inefficient binding/scavenging
of IL-33 resulting in enhanced disease severity, it is also plausible that elevated sST2 levels
reflect earlier high levels of IL-33 in infants. If the latter is true, then the timecourse of infection
(i.e. days post-infection) at the time of sampling will be an important factor as future data is
interpreted. In either case, these data cumulatively demonstrate a role for sST2 in RSV disease.
The exact role of sST2 is our neonatal mouse RSV model was not tested and therefore it is diffi-
cult to reconcile this human data with our data demonstrating increased cell bound ST2 and
IL-33 on ILC2s.
Surprisingly, early changes in RSV-induced IL-33 and ILC2s were age-dependent, as neona-
tal mice responded with robust IL-33 expression and a significant increase in ILC2s; while
adult mice failed to induce IL-33 or ILC2s. Importantly, we observed elevated (and positively
correlated) IL-33 and IL-13 in nasal aspirates of infants hospitalized with RSV infection. A lim-
itation of our human data is the lack of samples from uninfected infants or infants infected
with RSV but with mild (no medical intervention) or moderate (office visit) disease. With such
samples, it is possible that these data would yield more robust conclusions (i.e. IL-33 correlates
to RSV disease severity). The increase in IL-33 in nasal aspirates from infants along with our
mouse data cumulatively suggest that IL-33 and ILC2s are critical for the age-dependent devel-
opment of asthma following severe RSV infection during infancy and that they may be a plausi-
ble therapeutic target.
Infants that develop severe RSV bronchiolitis prior to 4 months of age are at increased risk
to develop childhood asthma [38]. Differential regulation of either IL-33 or ILC2s as a factor of
age is a previously unexplored area of developmental immunology that may further explain the
Th2-biased immunity observed during early life. IL-33 has been reported to be constitutively
produced (but not secreted), predominantly by non-hematopoietic (i.e., epithelial) cells in the
lung [39, 40]. It is produced as a full-length form, which is biologically active but confined to
the nucleus [41] where it functions as a transcriptional regulator [42]; this form can be released
upon tissue damage or necrosis to act as an alarmin for the surrounding tissue [43] or be pro-
teolytically cleaved into a highly active mature form by cathepsin G [44]. Furthermore, there is
evidence that IL-33 is inactivated by caspase-1 [45, 46] which is increased during inflamma-
some activation [47]. Our data suggest that the airway epithelium is a significant source of IL-
33 during neonatal RSV infection. Indeed, given the propensity for RSV to primarily infect the
airway epithelium and the sheer number of epithelial cells in the lung, it is likely that the bulk
of IL-33 secretion/release is epithelium-derived. Though outside the scope of the present study,
IL-33 and ILC2s in Infant RSV Infection
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we are investigating epithelial subsets within this context to determine which types of cells
within the epithelium are responsible.
Another product of inflammasome activation, IL-1β, suppresses IL-33 and ILC2s during
Th2-mediated disease [48]. Interestingly, we have previously demonstrated defective inflam-
masome activation in RSV-infected neonatal mice compared to adult mice and in human cord
blood mononuclear cells (MNCs) compared to adult peripheral blood MNCs [49]. It is there-
fore possible that a lack of caspase-1 activity and/or IL-1β production results in “unchecked”
IL-33 release in RSV-infected neonates/infants. Additionally, increased numbers of ILC2s have
been observed in fetal human lungs compared to adult lungs [50] and in human cord blood
MNCs compared to adult peripheral blood MNCs [51]. Despite these indications that IL-33
and ILC2s play a larger role in the immunity of neonates/infants, to date there have been no
studies focused on when/how these factors change during early development and their subse-
quent influence on immune responses.
The present study defines roles for ILC2s and IL-33 in a previously unrecognized disease,
and illuminates developmental variables as an area worthy of future consideration. The absence
of IL-33 (or IL-33 signaling via knockout of its receptor) completely abolished the severe RSV
disease phenotype in neonatal mice; while the administration of the cytokine during infection
in adult mice resulted in exacerbated Th2 inflammation, lung dysfunction, and airway mucus.
Age being a factor in IL-33 regulation has important implications for RSV research and pediat-




Mice were maintained in a specific-pathogen-free facility in ventilated microisolator cages.
BALB/c mice were purchased from Harlan Laboratories (Indianapolis, IN). Il1rl1-/- mice [52]
on a BALB/c background were generously provided by Dr. Hirohito Kita (Mayo Clinic) with
approval from Dr. Andrew McKenzie (Medical Research Council, UK). Breeders were time-
mated, and pups born on the same date were used for experiments. All animal protocols were
prepared in accordance with the Guide for the Care and Use of Laboratory Animals and
approved by the Institutional Animal Care and Use Committee at the University of Tennessee
Health Science Center.
RSV infection
RSV strain A2 (Advanced Biotechnologies; Columbia, MD) was propagated in Vero cells
grown in serum-free media (HyClone; Thermo Fisher), harvested using standard protocol [16,
17], and stored at -80°C until use. Adult mice (6–8 week old) or neonatal mice (5 d old) were
infected I.N. with RSV in serum-free media at a dose of 2 × 105 50% tissue culture infectious
dose (TCID50) per gram of body weight. Reinfection with RSV occurred 4 weeks after the initial
infection. Viral load was assessed in homogenized whole lung at 4 dpi by titer assay using the
Spearman and Karber TCID50 method [53] with a lower detection limit of 316 TCID50 ml
-1.
For UV-RSV, virus from the same stock was inactivated by exposure to 1800 mJ UV light
(Gene Linker; Bio-Rad; Hercules, CA). Inactivation was confirmed via viral titer assay.
IL-33 treatments
Three hr prior to RSV infection, neonatal mice received IL-33 neutralizing antibody (α-IL-33;
2 mg kg-1 in PBS per supplier’s recommendation; I.N.). Controls received Rat IgG isotype
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control. Recombinant IL-33 (rIL-33; Peprotech) was administered to adult mice (0.5 μg in PBS
0.1% BSA) [27] I.N. at 24 hr and 3 hr before infection. The volumes of all neonatal and adult
treatments were 10 μl and 50 μl, respectively. Controls received vehicle. IL-33 neutralizing anti-
body and isotype control were generously provided via MTA with Pfizer Inc.
Cytokine expression
Previously frozen lung samples were homogenized in T-PER reagent (Thermo Fisher; Wal-
tham, MA) in the presence of a protease inhibitor cocktail. Cytokine expression in whole lung
homogenate was determined by Platinum ELISA (eBioscience; San Diego, CA) and corrected
for total protein determined by BCA assay (Thermo Fisher).
Flow cytometry
Lung single-cell suspensions [54] were stained with a fixable viability marker, stained with an
antibody panel (below), and assayed on a FACS Canto II (BD; Franklin Lakes, NJ). For CD4 T
cell population identification and determination of IL-33 cell sources, cells were stimulated for
5 hr with phorbol-12-myristate-13-acetate (PMA; 5 ng ml-1) and ionomycin (500 ng ml-1) in
the presence of a protein transport inhibitor (GolgiPlug; BD) prior to intracellular staining
with CD3—eFluor450, CD4—PerCP, IFNγ—PE, and IL-4—PE-Cy7 or CD45—PerCP-Cy5.5,
EpCam—APC, CD31—PE-Cy7 (all eBioscience), and IL-33—PE (R&D Systems; Minneapolis,
MN). For ILC2 staining, cells were labeled with antibodies to CD3—PacBlue, CD19—PacBlue,
CD11c—PacBlue, CD11b—PacBlue, CD49b—PacBlue, F4/80—PacBlue, FcεRI—PacBlue, and
Sca-1—PE-Cy7, (all BioLegend; San Diego, CA), ST2—FITC (MD Bioproducts; St. Paul, MN),
Thy1.2 (CD90)—biotin (Southern Biotech; Birmingham, AL), Gata3—PE-Cy7 (BD), CD45—
PerCP-Cy5.5, CD25—APC-Cy7/PE, and ICOS—APC (all eBioscience). Data were analyzed
using FlowJo v10 (S1 Fig).
Lung function test
In anesthetized (ketamine/xylazine, 180/10 mg kg-1), tracheotomized mice, peak airway resis-
tance values in response to increasing doses of inhaled methacholine was measured using the
flexiVent system (Scireq; Montreal, Canada).
Bronchoalveolar cellularity
Mouse bronchoalveolar cells were isolated by lavage of the lungs with 1 ml PBS. Cells were
then counted, spun onto slides, and stained with Hema-3 kit (Thermo Fisher). Differential cell
counts were conducted in a blinded manner using standard morphological criteria.
Lung histopathology and in situ hybridization
Mouse lungs were retroperfused with PBS, then gravity-inflated with zinc-formalin. Following
fixation and paraffin embedding, 4 μm sections were prepared using standard procedures.
Slides were stained with periodic acid-Schiff (PAS) to observe mucus production. As previously
performed for quantification of mucus-producing cells [54], the number of PAS+ epithelial
cells was divided by the total number of epithelial cells in a respective airway; this was repeated
for at least 10 airways on each section, giving an average percentage. In situ hybridization of
IL-33 mRNA was performed on deparaffinized sections with RNAscope technology (Advanced
Cell Diagnostics; Hayward, CA) according to manufacturer’s instructions. All images were
acquired using an EVOS FL Auto (Life Technologies; Grand Island, NY) microscope.
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Cytokine measurements in nasal aspirates
During the winter seasons of 2013–2015, previously healthy children (<2 yr of age) testing pos-
itive for RSV by antigen and/or PCR (and negative for influenza) at Le Bonheur Children’s
Hospital were prospectively enrolled in a natural history study. Exclusion criteria included
diagnosed immunodeficiency, chronic lung disease, congenital heart disease, or had received
steroid treatment within the last month (patient demographics provided in S1 Table). Nasal
aspirates were obtained on the first day of clinical presentation (median of 3 days after first
symptom onset, IQR 2–5 days), and cell/mucus-free supernatants were stored at -80°C until
analysis. A subset of patients had an additional nasal aspirate sample obtained four weeks later.
Cytokine levels were determined by Milliplex human cytokine assay (Millipore, St. Charles,
MO) according to manufacturer’s instructions. All returned values that were below the limit of
detection (LOD) for the respective cytokine target were replaced with the LOD divided by the
square root of 2 [55]. This study was conducted with approval of the Institutional Review
Board of the University of Tennessee Health Science Center.
Statistics
Data were analyzed with Prism5 (Graphpad; La Jolla, CA), and presented as means ± s.e.m.
One-way or Two-way ANOVA with Bonferroni post-tests or student’s t-tests (both paired and
unpaired) were used, where appropriate. P values<0.05 were considered significant. For nasal
aspirate analyses, a Sign analysis was used for paired data and a Kendall’s tau correlation coeffi-
cient was computed to describe the correlation between IL-33 and IL-13.
Ethics statement
All animal protocols were prepared in accordance with the Guide for the Care and Use of Lab-
oratory Animals and approved (#14–045.0) by the Institutional Animal Care and Use Commit-
tee at the University of Tennessee Health Science Center.
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